Drug treatment in Asia

AFRICA

AMERICAS

ASIA

EUROPE

OCEANIA

PRIMARY DRUG AMONG PERSONS TREATED FOR DRUG PROBLEMS IN ASIA

2016 (or latest year available)

 

Country / Territory

 

Source

 

Treatment
Year ***

Distribution of main drugs in percentages*

 

Treatment
Provided **

 

Data
Primarily
Reflect

Cannabis

Opioids

Cocaine

ATS

Tranquilizers
and Sedatives

Hallucinogens

Solvents
and  Inhalants

Other †

Afghanistan

ARQ

2015

7.2%

92.8%

 

0.0%

0.0%

0.0%

0.0%

0.0%

18,609

a

Armenia

ARQ

2015

3.4%

95.1%

0.0%

0.0%

1.5%

0.0%

0.0%

0.0%

267

 

Azerbaijan

ARQ

2016

53.0%

41.0%

0.0%

0.0%

6.0%

0.0%

0.0%

0.0%

5,336

a

Bangladesh

DAINAP

2007/ 2009***

15.0%

76.9%

0.0%

0.0%

0.0%

0.0%

0.0%

0.0%

3,800

a

Bhutan

ARQ

2010

 

 

 

 

 

 

 

 

74

 

Brunei Darussalam

ARQ

2016

0.0%

0.0%

0.0%

100.0%

0.0%

0.0%

0.0%

0.0%

104

a

China

ARQ

2016

 

100.0%

 

 

 

 

 

 

162,000

k

China, Hong Kong SAR

Govt / ARQ

2008/ 2009***

6.0%

57.9%

0.0%

8.7%

0.0%

0.0%

0.0%

27.4%

12,557

j

China, Taiwan Province of China

NBCD   DOH

2009

0.1%

73.1%

0.0%

22.3%

4.2%

0.0%

 

0.0%

19,125

d

Cambodia

DAINAP

2015

 

 

 

 

 

 

 

 

12,712

 

Georgia

ARQ

2016

0.4%

94.1%

0.1%

1.1%

4.3%

0.0%

0.0%

0.0%

5,730

 

India

ARQ

2014-15

22.8%

71.3%

0.8%

0.2%

3.6%

0.2%

1.2%

0.0%

10,253

b,c

Indonesia

ARQ

2016

11.9%

4.9%

0.1%

69.4%

2.8%

 

 

3.9%

13,617

k

Iran (Islamic Republic of)

ARQ

2016

 

 

 

 

 

 

 

 

795,638

a

Israel

ARQ

2016

47.1%

22.7%

9.5%

1.9%

3.7%

1.8%

0.0%

13.4%

8,001

 

Japan

Govt. / DAINAP

2005/ 2012***

2.3%

0.0%

0.0%

55.1%

0.0%

0.0%

14.5%

28.2%

18,131

 

Jordan

ARQ

2015

83.5%

3.6%

0.1%

12.4%

0.0%

0.5%

0.0%

0.0%

1,448

k

Kazakhstan

ARQ

2016

2.8%

51.3%

0.0%

0.2%

0.1%

0.0%

0.9%

44.6%

4,950

a

Kuwait

ARQ

2009

28.4%

31.2%

0.5%

22.3%

16.1%

0.0%

1.5%

0.0%

197

d,f

Kyrgyzstan

ARQ

2016

20.0%

57.4%

0.0%

0.0%

0.0%

0.0%

4.7%

17.9%

190

b, c

Lao People's Democratic Republic

DAINAP

2015

0.1%

0.7%

0.0%

99.2%

0.0%

0.0%

0.0%

0.0%

1,419

 

Lebanon

ARQ

2016

13.3%

36.4%

16.3%

3.8%

5.5%

0.1%

0.3%

 

1,826

k

Macao SAR, China

ARQ

2016

3.3%

43.3%

3.3%

11.3%

0.3%

 

 

30.7%

573

k

Malaysia

ARQ/Gov.

2016

2.6%

57.4%

0.0%

39.7%

0.1%

 

0.0%

0.2%

8,568

a, c

Maldives

ARQ

2003

13.0%

87.0%

0.0%

0.0%

0.0%

0.0%

0.0%

0.0%

126

d,e

Mongolia

ARQ

2013

6.7%

13.3%

0.0%

3.3%

73.3%

3.3%

0.0%

0.0%

30

a

Myanmar

ARQ

2016

0.3%

71.5%

 

7.6%

 

 

 

 

9,258

a

Nepal

ARQ

2006

 

 

 

 

 

 

 

 

900

a

Oman

ARQ

2013

53.7%

0.0%

0.0%

1.9%

38.9%

3.1%

2.4%

0.0%

319

 

Pakistan

ARQ

2016

 

 

 

 

 

 

 

 

15,499

b

Philippines

ARQ

2016

18.7%

0.6%

0.8%

77.7%

1.0%

0.4%

 

0.7%

6,079

a, e, f

Qatar

ARQ

2008

 

 

 

 

 

 

 

 

150

a,d

Republic of Korea

ARQ

2016

21.2%

1.5%

 

77.3%

 

 

 

 

885

c, d, e, f

Saudi Arabia

ARQ

2016

26.1%

12.1%

0.0%

57.4%

4.0%

0.0%

0.4%

 

7,927

k

Singapore

ARQ

2016

7.5%

11.6%

0.0%

72.9%

0.5%

0.0%

1.7%

5.7%

1,263

k

Syrian Arab Republic

ARQ

2006

0.2%

94.9%

0.9%

0.0%

4.1%

0.0%

0.0%

0.0%

674

 

Sri Lanka

ARQ

2016

41.7%

58.3%

0.0%

 

0.0%

0.0%

0.0%

0.0%

2,355

a, f

Tajikistan

ARQ

2016

0.5%

91.8%

 

 

 

 

 

 

560

a

Thailand

ARQ

2016

8.8%

4.3%

0.0%

80.4%

 

 

1.0%

5.4%

172,518

a

Turkmenistan

ARQ

2016

4.9%

95.1%

 

 

 

 

 

 

1,602

a

United Arab Emirates

ARQ

2008/ 2009***

35.7%

64.3%

0.0%

0.0%

0.0%

0.0%

0.0%

0.0%

55

 

Uzbekistan

ARQ

2016

32.2%

51.2%

 

 

2.9%

 

0.8%

 

2,220

a

Viet Nam

DAINAP

2015

 

 

 

 

 

 

 

 

49,520

 

Total

   

 

 

 

 

 

 

 

 

1,377,065

 

Average

 

 

   17.0%

   46.4%

     1.1%

   25.8%

     5.8%

     0.4%

     1.1%

     6.4%

 

 

 

*      Definitions of treatment interventions, recording practices (including counting rules) and methods for determining the primary drug of abuse differ from country to country; percentages may fail to add up to 100 per cent owing to incomplete reporting, gaps in identifying primary drug of abuse and treatment for multiple drugs. In cases where the total of the reported values by drug type exceeded the reported value for all treatment, the percentages are expressed as a proportion of the total.

**    Figures may reflect number of persons or treatment episodes depending on the Member State; figures exclude alcohol and nicotine.

***  If multiple years are given, the second year specified is for the number of people treated (second to last column).

†    In addition to miscellaneous and unspecified drugs, the category "Other" includes substances not under international control.

Data primarily reflect (codes)

  1. Whole country
  2. Geographically limited reporting (eg the Capital city)
  3. Publicly funded treatment
  4. NGO/ privately funded treatment
  5. Inpatient/ hospitalization modality
  6. Outpatient modality
  7. Limited subpopulation (eg prison, youth, etc)
  8. Opioid substitution treatment (eg methadone)
  9. First-time treatment entrants (not returning clients)
  10. Treatment admissions (not persons)
  11. Partial coverage (geographical/treatment type)
  12. Prisons excluded
  13. Treatment entrants only